Provided by Tiger Fintech (Singapore) Pte. Ltd.

Design Therapeutics, Inc.

5.74
-0.4300-6.97%
Post-market: 5.50-0.2400-4.18%16:56 EDT
Volume:130.96K
Turnover:768.95K
Market Cap:326.88M
PE:-5.13
High:6.30
Open:6.18
Low:5.67
Close:6.17
52wk High:7.77
52wk Low:2.60
Shares:56.95M
Float Shares:26.28M
Volume Ratio:0.35
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1191
EPS(LYR):-0.8763
ROE:-26.77%
ROA:-19.02%
PB:1.53
PE(LYR):-6.55

Loading ...

Nasdaq Net Change Percentage Gainers & Losers

Dow Jones
·
Oct 03

Citizens JMP healthcare analysts hold an analyst/industry conference call

TIPRANKS
·
Oct 02

Design Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Justin D. Gover

Reuters
·
Sep 11

Design Therapeutics Appoints Justin Gover as Director

TIPRANKS
·
Sep 11

Design Therapeutics Appoints Industry Veteran Justin Gover to Board of Directors, Dr. Arsani William Steps Down

Reuters
·
Sep 11

Design Therapeutics Appoints Justin Gover to Board of Directors

THOMSON REUTERS
·
Sep 11

Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller

Benzinga_recent_news
·
Aug 30

Top Premarket Decliners

MT Newswires Live
·
Aug 26

Director William Arsani Reports Disposal of Common Shares of Design Therapeutics Inc

Reuters
·
Aug 15

Design Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Design Therapeutics Q2 net loss misses expectations

Reuters
·
Aug 08

Design Therapeutics Q2 Basic EPS USD -0.34

Reuters
·
Aug 08

Design Therapeutics Inc. Reports Q2 2025 Net Loss of $19.1 Million; R&D Expenses at $15.7 Million

Reuters
·
Aug 08

Design Therapeutics Highlights Progress Across Lead Genetac® Programs and Reports Second Quarter 2025 Financial Results

THOMSON REUTERS
·
Aug 08

Press Release: Design Therapeutics Highlights Progress Across Lead GeneTAC(R) Programs and Reports Second Quarter 2025 Financial Results

Dow Jones
·
Aug 08

Design Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
Aug 01

Design Therapeutics Inc. Concluded Annual Stockholder Meeting

Reuters
·
Jun 13

Design Therapeutics Faces FDA Clinical Hold on IND Application for U.S. Expansion of RESTORE-FA Trial

Reuters
·
Jun 04

Design Therapeutics Inc. Files Initial Beneficial Ownership Statement for Chris Storgard, Chief Medical Officer

Reuters
·
May 24

BRIEF-Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing

Reuters
·
May 08